Bethin is diet pills that help to lose weight  people with the so-called “clinical obesity”, as well as with the risk of heart failure.

Active substance of Bethin is Rimonabant, it is known under the name Acomplia in Europe and as Zimulti in the United States.

Active substance Rimonabant was discovered by scientists thanks to fortunate coincidence. Once, doctors’ attention attracted by the fact that smoking of a narcotic substance like hashish causes excessive appetite in the smoker and so the question arose: is it possible to achieve the opposite effect?  If hashish smoking stimulates receptors and causes appetite, then perhaps these receptors can be blocked or they can be manipulated in order to suppress the appetite. Bethin is a drug created by scientists in order to affect the area of the brain which controls satiety.

Cannabinoids in hashish stimulate Endocannabinoid System in the brain that causes an increase in appetite. Bethin acts vice versa, it blocks this area of the brain at a certain time, the effect of “satiety” or supressed appetite is caused by this fact. More specifically, Bethin affects the irritated CB1 receptors of the brain that produce lipids and are responsible for glucose metabolism, obesity and even addiction of tobacco and drug. In addition, Bethin contributes to the development of “good” cholesterol, known as high-density lipoprotein (HDL), herewith reducing triglyceride level.

People with high body mass index and obesity already know about the positive aspects of Bethin. World Health Organization (WHO) says about excessive body mass index in a coefficient of fat deposits more than 25% for men and 30% for women (30kg/m2). Bethin is appointed exclusively by medical prescription and only for people who are obese, whose weight represents a significant threat to their health and can cause the development of heart failure.

It should also be remember that Bethin is not a panacea against overweight and should be used in a complex with diet food and physical activity. Ground for the appointment of Bethin is exactly clinical obesity, this means that a patient tried to be treated by traditional diets and physical activities but did not achieve a significant result in weight loss.

Bethin does not have unpleasant and prolonged side effects. Insignificant number of patients can experience nervousness, increased excitability, insomnia or mild depression some time. It is believed that such manifestations are typical to drugs that affect the brain receptors. In some cases, Bethin medication can cause nausea and diarrhea, that is associated with individual intolerance to the drug components.

Indications:

Monaslim is used as an auxiliary means to diet and exercise in the treatment of adult patients with obesity (body mass index 30 kg/m2) with associated risk factors, such as type I diabetes or dyslipidemia.

Mode of administration: for adults, recommended dose is Monaslim 20mg/day (1 tablet) in the morning before breakfast. Patients should be warned of the need for strict adherence to prescribed Monaslim dosage. Obesity treatment should be started simultaneously with moderate low calorie diet.

Treatment duration with Monaslim pills is established by doctor. Safety and effectiveness of Monaslim after 2 years of use was not studied.

No dose adjustment is necessary in elderly patients. Monaslim diet pills should be taken carefully in patients over 75 years.

Monaslim should be used carefully in patients with moderate liver failure. Monaslim should not be used in patients with severe liver failure.

Contraindications:

Hypersensitivity to the active substance or any component of the drug, pregnancy and breast-feeding, severe liver failure, severe renal failure, galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption (due to the lactose content in the medication), severe depression and / or antidepressant treatment, children under 18 years.

SPECIAL INDICATIONS:

During Monaslim use, depressive disorders or mood changes with depressive symptoms were revealed in a group of patients (up to 10%) and suicidal mood – in some patients (1%). Monaslim diet pills should not be used in patients with suicidal mood and / or suicidal mood and depression in history, except cases when the potential benefit of the treatment exceeds the possible risk for individual patient.

OVERDOSE:

Experience of Monaslim overdose is limited. Limited number of patients used doses up to 300 mg in the study of tolerability. Herewith, it  was observed insignificantly pronounced symptoms: headache, euphoria, fatigue and insomnia.

Specific antidote of Monaslim pills does not exist, it is necessary to conduct maintenance treatment in case of overdose. This treatment should consist of general measures that are used in overdose, such as airway management, control of cardiovascular system function and general symptomatic and maintenance therapy.

Our online pharmacy offers you to buy Monaslim, as our prices are cheaper than in usual drugstore. Moreover, our online pharmacy provides you with the opportunity to buy Rimonabant at discount price. Buying at our online pharmacy you will save your time and money.

A lot of different ways and methods are advertised for weight loss:

• Starvation and diet;
• Physical and physiotherapeutic methods;
• East methods – by means of acupuncture;
• Psychotherapeutic and hypnotic methods
• Surgical methods;
• Exotic methods;

Each of them has its place and effectiveness. However, some of them not only useless but also harmful for health. Many people, falling under the influence of advertising or presentation, get sometimes irreparable consequences.

Brief characteristics of popular weight loss methods.

Starvation and a rigid diet

If this is done without the supervision of specialists, most often this leads to the opposite result and here’s why. Let’s say you consumed 2,000 calories of food a day and then went on a diet, corresponding to 1000 kcal. But the body did not understand that you were joking. It regards this as onset of famine time and quickly rebuilds your metabolism for more economical mode.

As a result, 1 500 calories a day becomes enough for the body to meet the needs. After a diet, you return to the previous 2000 kcal, this means 500 kcal are excessive. What do you think, where they go? … Turn into fat! And you wonder that you gain weight by leaps and bounds, however eat as before. Nature is not to be trifled with!

Weight loss, using exercise

It is necessary individually to approach to the choice of physical activity, since for some people walking will be a load, but for others – intensive training in the gym. This choice depends on age, health, ….

If you lead inactive lifestyle, start with walking, gradually increasing its duration and speed. After a while, small distances can be replaced for jogging This is the first period, which is called adaptation period to physical loads. When you feel that these loads have become habitual and enjoyable for you, go to the second stage – exercise.

Medicines for weight loss

Drugs to treat obesity (obesity, rather than getting rid of 3-5-7 kg of excess weight!) can be divided into three groups according to the mechanism of action:

• Drugs that reduce food intake: sibutramine (Meridia, Lindaxa, Obestat, Sibutrex, etc.).
• Drugs that increase energy consumption: thermogenic sympathomimetics (ephedrine / caffeine).
• Drugs that reduce the absorption of nutrients: Xenical (Orlistat).

Rimoslim (Rimonabant) – is the first representative of a new medication class whose action is based on the blocking the part of the brain which regulates food intake and activity of processing of sugar and fats in the blood. Rimoslim tablets regulates the need in the consumption of tasty, sweet or fatty food. Simply said Rimoslim medicine allows very quickly to lose weight. When using Rimoslim, average weight loss is 6.5 kg by the end of the first treatment year, 5.3 kg – in patients with type 2 diabetes.

If you want to buy Slimona online without prescription you should first of all consult your doctor.

Weight loss prevents or weakens the action of a number of obesity-related metabolic risk factors (insulin resistance, type 2 diabetes, dyslipidemia, hypertension). Average weight loss is 6.5 kg by the end of the first year of treatment with Riobant weight loss drug, 5.3 kg – in patients with type 2 diabetes. Basically, weight loss is observed during the first 9 months of Riobant treatment, the drug efficacy (regarding the maintenance of reduced body weight) remains up to 2 years. In patients with dyslipidemia or without it  HDL concentration increases (on average by 16.4%) and TG concentration decreases (on average by 6.9%) by the end of the first year of treatment. Approximately 50% of the observed changes in the concentration of HDL and TG (in a dose of Acomplia 20mg) did not depend on weight loss.

Special instructions:

Obesity – is a condition which can be associated with depression. In Riobant use, depressive disorders, mood changes with depressive symptoms (up to 10%), as well as the occurrence of suicidal thoughts (1%) can develop, so Riobant medication should be prescribed carefully for patients with suicidal thoughts and / or depressive disorders in history. Patients (especially with a history of depression), as well as their relatives and friends should be informed about the possibility of development such states and in the case of their occurrence, it is necessary immediately to call the doctor. If depression develops during Riobant treatment, the treatment should be stopped. There were no differences in the frequency of epileptic seizures in patients, treated with Riobant tablets and placebo. However, Riobant for weight loss should be used carefully in these patients.

Riobant interaction:

Riobant  in vitro is subjected to metabolism with participation of CYP3A and amidohydrolase, so CYP3A isoenzyme inhibitors increase the systemic exposition of Riobant; CYP3A inductors reduce exposition of Riobant. It is recommended to be careful when taking Riobant tablets together with potent inhibitors of CYP3A isoenzyme (ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, nefazodone). Simultaneous use of Riobant with inductors of CYP3A isoenzymes (rifampicin, phenytoin, phenobarbital, carbamazepine, Hypericum perforatum medications) can reduce Riobant concentration in the plasma and lead to efficiency decrease. Simultaneous use of orlistat, ethanol or lorazepam does not significantly affect Riobant concentration  in the plasma.

Also just now, you can buy Acomplia online!

Do not buy Riobant without prescription without first talking to your doctor. Online pharmacies provide with the possibility to buy Slimona no prescription by ordering the delivery of Slimona diet pills from any world country.

Rimonabant is active substance of Slimona

Rimonabant – is the first representative of a new class of drugs – cannabinoid receptor type I (CB1). Rimonabant modulates hyperactive system of endocannabinoid by selective binding of central and peripheral CB1 receptors. It is obtained the research results, in respect of reduction of severity of risk factors for cardiovascular diseases as a result of decrease the amount of abdominal fat and appropriate improvement of metabolic parameters that go beyond the expected, based on weight loss.

Obesity is the biggest public health problem and one of the most frequent causes of death worldwide, mainly due to cardiovascular disease. Obesity is usually determined by body mass index (BMI), however recent studies have shown that visceral (abdominal) obesity (its degree directly correlates with the size of waist circumference) is the best factor for predicting the risk of acute coronary syndrome than body weight or BMI. In 44% of adult US population, waist circumference exceeds the risk level (40 inches for men and 35 inches for women). Visceral type of obesity is associated with the causes of metabolic risk factors, such as dyslipidemia or insulin resistance that can lead to diabetes, myocardial infarction, stroke and other cardiovascular diseases. Reduction in the degree of visceral obesity degree is a recognized priority for preventing cardiovascular disease.

Cardiovascular risk factors, associated with obesity became more pronounced. Excessive amount of abdominal fat is increasingly recognized as one of the most informative precursor of future cardiovascular complications. Results of two-year Rio-North America study confirm that Slimona is an innovative and promising means for long-term correction of obesity and associated cardiovascular risk factors in patients with abdominal obesity.

Slimona and endocannabinoid system

Endocannabinoid system is a recently discovered physiological system in the body which, experts believe, plays an important role in the central and peripheral regulation of energy balance, metabolism of glucose and lipids, as well as control of tobacco addiction.

CB1 receptors are found in the brain and in peripheral body tissues, such as adipocytes that are associated with the metabolism of lipids and glucose. Consumption of excessive amounts of food or chronic use of tobacco leads to hyperresponsiveness of endocannabinoid system. This can launch the mechanism of increase in food intake and fat accumulation or in the case of smoking, sustained tobacco addiction.

International name: Rimonabant

Active substance: Rimonabant

Pharmaceutical form: film-coated tablets

Zimulti is a registered trademark of Sanofi-Aventis.

Pharmacological action:

Zimulti is selective cannabinoid-1 receptor antagonist, which inhibits the pharmacological effects of cannabinoid agonists in vitro and in vivo. Endocannabinoid system is a physiological system, which is present in the brain and peripheral tissues (including adipocytes) which affects energy balance, body mass and metabolism of glucose and fat. It regulates the need in consumption of tasty, sweet or fatty food thanks to its presence in neurons of the mesolimbic system.

Indications:

Zimulti is intended for obesity (body mass index over 30 kg / m²), for overweight (body mass index over 27 kg / m²) with associated type 2 diabetes or dyslipidemia.

Contraindications:

Hypersensitivity, severe form of hepatic and / or renal failure, depressive episode which is currently existing and / or continued therapy of depressive episode, simultaneous use of Zimulti with antidepressants (due to the lack of sufficient experience of use), pregnancy, breastfeeding, infancy, lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Side effects:

Most common side effects: nausea, mood changes with depressive symptoms, depressive disorders, anxiety, dizziness. From nervous system – often – dizziness, amnesia, sleep disorder, including insomnia, parasomnias, depressive disorders (3.2% of cases), mood change with depressive symptoms, anxiety, irritability, nervousness, decreased sensitivity, sciatica, rarely – emotional lability, panic symptoms, suicidal thoughts, aggressive behavior, anger, apathy, dysphoria; hallucinations. From cardiovascular system: hot flashes. From digestive system: very often – nausea; often – vomiting, diarrhea, gastroenteritis, rare – hiccup. For the skin: often – itching, hyperhidrosis, rarely – night sweats. From musculoskeletal system: often – muscle cramps, spasms, tendonitis, sprain.

These are not all side effects and other can occur. Contact your doctor for medical consultation about side effects.

You have the possibility to buy Zimulti at our online pharmacy, since we guarantee you low cost, safety and effectiveness of Zimulti. It is very simple and convenient to buy Zimulti online, as you do not have to leave your home. Order Zimulti online takes 5 minutes.